Newsletter Subject

Why this play is blowing past Nvidia (up 32% last week)

From

dynamicwealthresearch.co

Email Address

info@e.dynamicwealthresearch.co

Sent On

Wed, Jun 26, 2024 12:56 PM

Email Preheader Text

How long will plays have the wind at their back? June 26, 2024 Hi Reader This bull market could real

How long will plays have the wind at their back? [DWR Logo]( June 26, 2024 Hi Reader This bull market could really have some legs and last week we saw some proof of the massive potential. The proof was a big jump from Sarepta Therapeutics (SRPT). The stock soared 32% last week. The catalyst was a unique type of FDA announcement. It wasn’t a traditional “go” or “no go” decision. Instead it was something a bit different that points to where some big gains will be had. Here’s the story. Sarepta has developed a single-dose gene therapy for Duchenne muscular dystrophy (DMD) called Elevidys. DMD is - thankfully - a rare disorder that affects 15,000 people in the U.S. Elevidys was previous approved as a treatment for just a tiny part of this group. It was approved for Boston Children’s Hospital says, “Elevidys is for boys ages 4 or 5 who are still able to walk and have had a genetic test confirming that they have DMD.” That was only about 10% of all DMD patients. The recent FDA announcement opens up the market massively. Elevidys is now approved as a treatment for an estimated 80% of DMD patients. That’s an 8X increase that takes the potential market from about 1,500 to more than 10,000. This is a small market, but Elevidys is a very expensive treatment.. Elevidys can cost anywhere between $3.2 million (according to two publicly available estimates). As a result, this approval is potentially worth billions of dollars for Sarepta and why the stock jumped so much. There’s a bigger storyline here too. This is just one example of how gene therapies could be one of the biggest growth trends of the next decade. This is staggering growth potential and we’re still early. [nvidia] But it gets even better. Biotech, as a sector, is still out-of-favor and why good news like Sarepta received sends biotech plays soaring higher. [Click here to see why the wind could be at biotech’s back for years to come.]( [Read More Button]( Dynamic Wealth Research 2010 West Avenue K #623 Lancaster, California 93536 We are sending this message to {EMAIL}. [UNSUBSCRIBE]( | [PRIVACY POLICY](

Marketing emails from dynamicwealthresearch.co

View More
Sent On

03/12/2024

Sent On

02/12/2024

Sent On

26/11/2024

Sent On

06/11/2024

Sent On

01/11/2024

Sent On

30/10/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.